Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 24

Sort by

Sort Order Select

Journal Articles

Delineation of Predictive Features of AML Patients with Recurrent Relapse Who Achieved Repeated Complete Remission after Multiple Re-Induction and Consolidation Therapies

Irene Graf, Georg Greiner, Karoline V. Gleixner, Susanne Herndlhofer, Gabriele Stefanzl, Paul Knöbl, Alexander Hauswirth, Manja Meggendorfer, Ulrich Jaeger, Constance Baer, Torsten Haferlach, Gregor Hoermann, Peter Valent, Wolfgang R. Sperr

Blood (2022) 140 (Supplement 1): 11634–11635.

https://doi.org/10.1182/blood-2022-162588

Published: 2022

Journal Articles

NT-Probnp As Personalized Medicine Tool and New Biomarker Predicting Response to Chemotherapy and Survival in AML

Irene Graf, Georg Greiner, Rodrig Marculescu, Karoline V. Gleixner, Susanne Herndlhofer, Gabriele Stefanzl, Paul Knoebl, Ulrich Jaeger, Alexander Hauswirth, Ilse Schwarzinger, Renate Thalhammer, Michael Kundi, Gregor Hoermann, Gerlinde Mitterbauer-Hohendanner, Peter Valent, Wolfgang R. Sperr

Blood (2021) 138 (Supplement 1): 3435.

https://doi.org/10.1182/blood-2021-149526

Published: 2021

Journal Articles

Impact of HFE gene Variants on Iron Overload, Overall Survival and Leukemia-Free Survival in Myelodysplastic Syndromes

Mathias A. Schneeweiss, Greiner Georg, MD PhD, Susanne Herndlhofer, Julia Schellnegger, Maria-Theresa Krauth, MD, Friedrich Wimazal, MD, Corinna Steinhauser, Renate Thalhammer, MD, Ilse Schwarzinger, MD, Harald Esterbauer, MD PhD, Manuela Födinger, Peter Valent, MD, Wolfgang R. Sperr, MD

Blood (2019) 134 (Supplement_1): 4269.

https://doi.org/10.1182/blood-2019-123390

Published: 2019

Journal Articles

Cardiovascular Scoring and Age-Related Mutations Predict the Occurrence of Adverse Vascular Events in CML Patients during Nilotinib Therapy

Emir Hadzijusufovic, DVM, Gregor Hoermann, MD, Susanne Herndlhofer, Wolfgang R. Sperr, MD, Bernd Jilma, MD, Gerit H. Schernthaner, MD, Peter Valent, MD

Blood (2017) 130 (Supplement 1): 1619.

https://doi.org/10.1182/blood.V130.Suppl_1.1619.1619

Published: 2017

Journal Articles

Hydroxyurea Induces Growth Inhibition in BCR-ABL1 T315I+ Clones and Synergizes with Ponatinib in Killing TKI-Resistant CML Cells

Mathias A Schneeweiss, MD, Konstantin Byrgazov, PhD, Chantal B Lucini, PhD, Susanne Herndlhofer, Wolfgang R. Sperr, MD, Thomas Lion, PhD, Gregor Hoermann, Michael W. Deininger, MD PhD, Peter Valent, MD, Karoline V Gleixner, MD

Blood (2016) 128 (22): 5425.

https://doi.org/10.1182/blood.V128.22.5425.5425

Published: 2016

Journal Articles

Evaluation of Cell Surface Markers and Targets in Leukemic Stem Cells (LSC) Reveals Distinct Expression Profiles, Unique Drug Effects, and Specific Checkpoint Regulation in AML LSC and CML LSC

Irina Sadovnik, MSc, Harald Herrmann, MD, Katharina Blatt, MSc, PhD, Gregor Eisenwort, MD PhD, Niklas Mueller, MD, Gabriele Stefanzl, Gregor Hoermann, Susanne Herndlhofer, Karin Bauer, PhD, Barbara Peter, DVM, Rene Gaupmann, MD, Axel Schulenburg, MD, Wolfgang R. Sperr, MD, Peter Valent, MD

Blood (2016) 128 (22): 4234.

https://doi.org/10.1182/blood.V128.22.4234.4234

Published: 2016

Journal Articles

Intensive Post-Remission Consolidation with G-CSF-Support: Tolerability, Safety, Reduced Hospitalization, and Efficacy of a New Treatment Protocol for AML Patients ≥60 Years

Wolfgang R. Sperr, MD, Susanne Herndlhofer, Karoline V Gleixner, MD, Michael Girschikofsky, MD, Ansgar Weltermann, MD, Sigrid Machherndl-Spandl, MD, Thamer Sliwa, MD, Rainer Poehnl, MD, Buxhofer-Ausch Veronika, MD, Karin Strecker, MD, Paul Knoebl, MD, Ulrich Jaeger, Klaus Geissler, MD, Michael Kundi, MD, Peter Valent, MD

Blood (2016) 128 (22): 2797.

https://doi.org/10.1182/blood.V128.22.2797.2797

Published: 2016

Journal Articles

Maintenance with Histamine and IL-2 Induces a Marked Expansion of Activated CD56 bright NK Cells in Acute Myeloid Leukemia

Angelica Cuapio, Dr. MD, Mirte Post, Sabine Cerny-Reiterer, Dr., Markus Osl, Volker Huppert, PhD, Karoline V Gleixner, MD, Susanne Herndlhofer, Wolfgang R Sperr, MD, Peter Valent, MD, Erhard Hofer, Dr.

Blood (2014) 124 (21): 1422.

https://doi.org/10.1182/blood.V124.21.1422.1422

Published: 2014

Journal Articles

Further Evaluation of Pro-Atherogenic and Anti-Angiogenic Effects of Nilotinib in Mice and in Patients with Ph-Chromosome+ CML

Blood (2014) 124 (21): 1800.

https://doi.org/10.1182/blood.V124.21.1800.1800

Published: 2014

Journal Articles

Dipeptidylpeptidase IV (CD26) defines leukemic stem cells (LSC) in chronic myeloid leukemia

Harald Herrmann, Irina Sadovnik, Sabine Cerny-Reiterer, Thomas Rülicke, Gabriele Stefanzl, Michael Willmann, Gregor Hoermann, Martin Bilban, Katharina Blatt, Susanne Herndlhofer, Matthias Mayerhofer, Berthold Streubel, Wolfgang R. Sperr, Tessa L. Holyoake, Christine Mannhalter, Peter Valent

Blood (2014) 123 (25): 3951–3962.

https://doi.org/10.1182/blood-2013-10-536078

Published: 2014

Includes: Supplemental data

Journal Articles

Imatinib Inhibits SCF-Induced Development Of Human Mast Cells In Vitro and Induces Profound and Selective Mast Cell Deficiency In Patients With Ph+ CML

Sabine Cerny-Reiterer, D.V.M, Anja Rabenhorst, Msc, Ph.D., Gabriele Stefanzl, Msc, Susanne Herndlhofer, Katharina Blatt, MSc, Ph.D., Gregor Hoermann, M.D., Ph.D., Leonhard Muellauer, M.D., Sigrid Baumgartner, M.D., Christine Beham-Schmid, M.D., Wolfgang R Sperr, M.D., Werner Linkesch, M.D., Christine Mannhalter, M.D., Michel Arock, PharmD, Ph.D, Karin Hartmann, M.D., Peter Valent

Blood (2013) 122 (21): 3988.

https://doi.org/10.1182/blood.V122.21.3988.3988

Published: 2013

Journal Articles

Phenotyping Of Leukemic Stem Cells In Ph+ ALL and Ph- ALL Reveals Unique Profiles Of Markers and Targets In Distinct Disease Variants

Sabine Cerny-Reiterer, D.V.M, Katharina Blatt, MSc, Ph.D., Harald Herrmann, M.D., Gregor Eisenwort, M.D., Ph.D, Susanne Herndlhofer, Heinz Sill, M.D., Werner Rabitsch, MD, Christine Mannhalter, M.D., Alexander Hauswirth, M.D., Wolfgang R Sperr, M.D., Ulrich Jaeger, Peter Valent

Blood (2013) 122 (21): 1654.

https://doi.org/10.1182/blood.V122.21.1654.1654

Published: 2013

Journal Articles

The Oncogenic Transcription Factor STAT5 Triggers Aberrant Expression Of CD25 (IL-2RA) In Neoplastic Stem Cells In Ph + CML

Irina Sadovnik, M.Sc., Harald Herrmann, M.D., Sabine Cerny-Reiterer, D.V.M, Wolfgang Warsch, Ph.D., Andrea Hoelbl, Ph.D., Katharina Blatt, MSc, Ph.D., Barbara Peter, D.V.M., Gabriele Stefanzl, Msc, Gregor Hoermann, M.D., Ph.D., Susanne Herndlhofer, Berthold Streubel, M.D., Wolfgang R Sperr, M.D., Christine Mannhalter, Ph.D., Veronika Sexl, MD, Peter Valent

Blood (2013) 122 (21): 3979.

https://doi.org/10.1182/blood.V122.21.3979.3979

Published: 2013

Journal Articles

Nilotinib Exerts Direct Pro-Atherogenic and Anti-Angiogenic Effects On Vascular Endothelial Cells: A Potential Explanation For Drug-Induced Vasculopathy In CML

Hadzijusufovic Emir, DVM, Karin Albrecht-Schgoer, PhD, Kilian Huber, PhD, Florian Grebien, PhD, Gregor Eisenwort, MD, PhD, Wilfried Schgoer, MD, PhD, Christoph Kaun, Susanne Herndlhofer, Markus Theurl, PhD, Sabine Cerny-Reiterer, D.V.M., Gregor Hoermann, M.D., Ph.D., Wolfgang R Sperr, M.D., Rix Uwe, PhD, Johann Wojta, PhD, Dominik Wolf, MD, Giulio Superti-Furga, PhD, Rudolf Kirchmair, MD, Peter Valent

Blood (2013) 122 (21): 257.

https://doi.org/10.1182/blood.V122.21.257.257

Published: 2013

Journal Articles

Serum Tryptase Is a Strong Predictive Biomarker That Improves Prognostication in Ph+ Chronic Myeloid Leukemia.

Wolfgang R. Sperr, M.D., Thomas Pfeiffer, Michael Kundi, MD, Christian Sillaber, MD, Susanne Herndlhofer, Peter Valent, MD

Blood (2012) 120 (21): 2783.

https://doi.org/10.1182/blood.V120.21.2783.2783

Published: 2012

Journal Articles

Expression of the CAMPATH-1 Antigen (CD52) on CD34+/CD38- Progenitor Cells in Patients with 5q- MDS and in a Subset of AML

Katharina Blatt, M.Sc., Harald Herrmann, M.D., Sabine Cerny-Reiterer, D.V.M., Susanne Herndlhofer, Wolfgang R. Sperr, M.D., Peter Valent, M.D.

Blood (2011) 118 (21): 1728.

https://doi.org/10.1182/blood.V118.21.1728.1728

Published: 2011

Journal Articles

The Leukemic Stem Cell (LSC) in Ph + CML Is a CD34 + /CD38 − /Lin − Cell That Co-Expresses Dipeptidylpeptidase IV (CD26) and Disrupts LSC-Niche Interactions by Degrading the CXCR4 Ligand SDF-1α

Harald Herrmann, M.D., Irina Sadovnik, M.Sc., Sabine Cerny-Reiterer, D.V.M., Katharina Blatt, M.Sc., Viviane Ghanim, M.D., Susanne Herndlhofer, Gregor Hoermann, M.D., Thomas Rülicke, D.V.M., Michael Willmann, D.V.M., Gerlinde Mitterbauer-Hohendanner, M.D., Matthias Mayerhofer, M.D., Wolfgang R. Sperr, M.D., Peter Valent, M.D.

Blood (2011) 118 (21): 961.

https://doi.org/10.1182/blood.V118.21.961.961

Published: 2011

Journal Articles

Nilotinib Exerts Direct Effects on Vascular Endothelial Cells and May Act As a Co-Trigger of Atherosclerosis in Patients with Ph+ CML

Emir Hadzijusufovic, DVM, Susanne Herndlhofer, Karl J. Aichberger, MD, PhD, Viviane Ghanim, M.D., Verena Suppan, BSc, Sabine Cerny-Reiterer, D.V.M., Wolfgang R Sperr, MD, Peter Valent, M.D.

Blood (2011) 118 (21): 2753.

https://doi.org/10.1182/blood.V118.21.2753.2753

Published: 2011

Journal Articles

Karyotype Plus NPM1 Mutation Status Defines a Group of Elderly Patients with AML (≥60 Years) Who Benefit From Intensive Post-Induction Consolidation Therapy

Wolfgang R. Sperr, MD, Otto Zach, PhD, Iris Poell, Michael Kundi, MD, Susanne Herndlhofer, Ulrich Jaeger, MD, Paul Knoebl, MD, Ansgar Weltermann, MD, Peter Valent, M.D.

Blood (2011) 118 (21): 2504.

https://doi.org/10.1182/blood.V118.21.2504.2504

Published: 2011

Journal Articles

BCR/ABL+ CML Stem Cells (CD34+/CD38-) Express High Levels of CD33 and Are Responsive to a CD33-Targeting Drug: a New Potential Concept for Eradication of CML Stem Cells.

Harald Herrmann, M.D., Sabine Cerny-Reiterer, D.V.M., Karoline V. Gleixner, M.D., Katharina Blatt, M.Sc., Susanne Herndlhofer, Hermine Agis, M.D., Werner Rabitsch, M.D., Berthold Streubel, M.D., Gerlinde Mitterbauer-Hohendanner, M.D., Wolfgang R. Sperr, M.D., Christian Sillaber, M.D., Peter Valent, M.D.

Blood (2010) 116 (21): 3382.

https://doi.org/10.1182/blood.V116.21.3382.3382

Published: 2010

NARROW

Delineation of Predictive Features of AML Patients with Recurrent Relapse Who Achieved Repeated Complete Remission after Multiple Re-Induction and Consolidation Therapies

NT-Probnp As Personalized Medicine Tool and New Biomarker Predicting Response to Chemotherapy and Survival in AML

Impact of HFE gene Variants on Iron Overload, Overall Survival and Leukemia-Free Survival in Myelodysplastic Syndromes

Cardiovascular Scoring and Age-Related Mutations Predict the Occurrence of Adverse Vascular Events in CML Patients during Nilotinib Therapy

Hydroxyurea Induces Growth Inhibition in BCR-ABL1 T315I+ Clones and Synergizes with Ponatinib in Killing TKI-Resistant CML Cells

Evaluation of Cell Surface Markers and Targets in Leukemic Stem Cells (LSC) Reveals Distinct Expression Profiles, Unique Drug Effects, and Specific Checkpoint Regulation in AML LSC and CML LSC

Intensive Post-Remission Consolidation with G-CSF-Support: Tolerability, Safety, Reduced Hospitalization, and Efficacy of a New Treatment Protocol for AML Patients ≥60 Years

Maintenance with Histamine and IL-2 Induces a Marked Expansion of Activated CD56 bright NK Cells in Acute Myeloid Leukemia

Further Evaluation of Pro-Atherogenic and Anti-Angiogenic Effects of Nilotinib in Mice and in Patients with Ph-Chromosome+ CML

Dipeptidylpeptidase IV (CD26) defines leukemic stem cells (LSC) in chronic myeloid leukemia

Imatinib Inhibits SCF-Induced Development Of Human Mast Cells In Vitro and Induces Profound and Selective Mast Cell Deficiency In Patients With Ph+ CML

Phenotyping Of Leukemic Stem Cells In Ph+ ALL and Ph- ALL Reveals Unique Profiles Of Markers and Targets In Distinct Disease Variants

The Oncogenic Transcription Factor STAT5 Triggers Aberrant Expression Of CD25 (IL-2RA) In Neoplastic Stem Cells In Ph + CML

Nilotinib Exerts Direct Pro-Atherogenic and Anti-Angiogenic Effects On Vascular Endothelial Cells: A Potential Explanation For Drug-Induced Vasculopathy In CML

Serum Tryptase Is a Strong Predictive Biomarker That Improves Prognostication in Ph+ Chronic Myeloid Leukemia.

Expression of the CAMPATH-1 Antigen (CD52) on CD34+/CD38- Progenitor Cells in Patients with 5q- MDS and in a Subset of AML

The Leukemic Stem Cell (LSC) in Ph + CML Is a CD34 + /CD38 − /Lin − Cell That Co-Expresses Dipeptidylpeptidase IV (CD26) and Disrupts LSC-Niche Interactions by Degrading the CXCR4 Ligand SDF-1α

Nilotinib Exerts Direct Effects on Vascular Endothelial Cells and May Act As a Co-Trigger of Atherosclerosis in Patients with Ph+ CML

Karyotype Plus NPM1 Mutation Status Defines a Group of Elderly Patients with AML (≥60 Years) Who Benefit From Intensive Post-Induction Consolidation Therapy

BCR/ABL+ CML Stem Cells (CD34+/CD38-) Express High Levels of CD33 and Are Responsive to a CD33-Targeting Drug: a New Potential Concept for Eradication of CML Stem Cells.

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only